1. Pharmacodynamic studies with the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839;Albanell;Semin. Oncol.,2001
2. UK Medical Research Council randomised, multicentre trial of interferon-alpha n1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response;Allan;Lancet,1995
3. Continuous administration of ZD1839 (Iressa), a novel oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), in patients with five selected tumor types: evidence of activity and good tolerability;Baselga;Proc. Am. Soc. Clin. Oncol.,2000
4. Evaluation of the safety and efficacy of an oral molecularly-targeted therapy, STI571, in patients (Pts) with unresectable or metastatic gastrointestinal stromal tumors (GISTS) expressing C-KIT (CD117);Blanke;Proc. Am. Soc. Clin. Oncol.,2001
5. ERBIN: a basolateral PDZ protein that interacts with the mammalian ERBB2/HER2 receptor;Borg;Nat. Cell Biol.,2000